| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Isotope-labeled ceramide; no intrinsic receptor or enzyme agonist/antagonist activity. Endogenous C16-ceramide is a bioactive sphingolipid that regulates apoptosis, cell cycle progression, and membrane properties, and serves as a precursor to sphingomyelin and glycosphingolipids. The deuterated standard is used exclusively as an analytical surrogate for C16-ceramide quantification and does not modulate ceramide-metabolizing enzymes or ceramide-mediated signaling.
|
|---|---|
| ln Vitro |
In the process of developing new drugs, stable heavy isotopes of carbon, hydrogen, and other elements have been added to pharmacological molecules, mostly as quantitative tracers. Due to its potential effects on medication pharmacokinetics and metabolic properties, deuteration is a matter for worry [2].
The d9-C16-ceramide standard shows no measurable intrinsic bioactivity and is not used for potency screening. Endogenous C16-ceramide is a major ceramide species in plasma and tissues; the d9 form co-elutes with the analyte and corrects for extraction recovery, ionization efficiency, and matrix effects, enabling accurate quantification of C16-ceramide across biological matrices. |
| ln Vivo |
No intrinsic in vivo pharmacological activity has been reported for the deuterated standard. Endogenous C16-ceramide accumulates in metabolic and cardiovascular disease and contributes to apoptosis and inflammation; the d9 standard supports in vivo quantification of C16-ceramide in plasma and tissue and enables studies of ceramide metabolism and sphingolipid signaling in animal models.
|
| Enzyme Assay |
LC-MS/MS ceramide quantification: add C16-Ceramide-d9 to the sample before lipid extraction; extract sphingolipids with chloroform/methanol or an MTBE-based protocol; separate on a reversed-phase C18 column; monitor the specific m/z transition of the d9 standard and the corresponding unlabeled C16-ceramide transition. Quantification is by isotope-dilution calibration using peak-area ratios.
|
| Cell Assay |
Cell-based ceramide profiling: culture cells under conditions that modulate ceramide metabolism or stress responses, harvest and quench metabolism, add the d9-C16-ceramide internal standard, extract sphingolipids, and analyze by LC-MS/MS.
|
| Animal Protocol |
In vivo tissue ceramide analysis: collect plasma or tissue at defined time points, add C16-Ceramide-d9 before homogenization, extract sphingolipids, and quantify C16-ceramide by LC-MS/MS.
|
| References |
| Molecular Formula |
C34H58D9NO3
|
|---|---|
| Molecular Weight |
546.96
|
| CAS # |
2260669-51-8
|
| Related CAS # |
C16-Ceramide;24696-26-2
|
| Appearance |
White to off-white solid powder
|
| SMILES |
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])CCCCCCCCCCCC(N[C@@H](CO)[C@H](O)/C=C/CCCCCCCCCCCCC)=O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8283 mL | 9.1414 mL | 18.2829 mL | |
| 5 mM | 0.3657 mL | 1.8283 mL | 3.6566 mL | |
| 10 mM | 0.1828 mL | 0.9141 mL | 1.8283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.